More articles about Drug Discovery & Development

The companies will build and screen novel DNA-encoded libraries for use by Pfizer in its drug discovery efforts.

The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.

At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.

The firms will use the FoundationOne assay to characterize tumors and their microenvironment to find predictive measures of response to cancer immunotherapies.

Backed by VC firm Third Rock Ventures, Tango will develop new cancer therapies using sequencing and CRISPR/Cas9 genome editing in target discovery and development.  

The company, which is collaborating with Myeloma Crowd, will use the newly-licensed minicircle DNA technology to develop therapies for multiple myeloma.

The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.

The gene-gene interactions research could lead to new therapies targeting cells with particular mutations, or combinations of targeted therapies.

The companies aim to offer integrated chemistry and biology services for ion channel drug discovery.

Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.

The companies aim to develop a genomic test to differentiate respiratory allergens from irritants to help with drug discovery.

The deal is expected to strengthen MedDay's existing cerebrospinal fluid-based metabolomics research platform.

Under the terms of the deal, HDB will have access to Luxcel's assays and technologies for mitochondrial function, metabolism, and toxicity.

The firm is counting on its experience integrating data from the oil and gas industry to change the way pharmaceutical data scientists work.

The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center.

Exosome Dx will help further Merck's drug development efforts in oncology and other areas using its exosome-based nucleic acid and protein detection technology.

IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.

The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.

The firm has secured rights to use CRISPR in cell lines for biomanufacturing and will work with Solentim to increase editing throughput while decreasing costs.

Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.

Pages

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.